Vertex Pharmaceuticals Inc (VRTX) 108.16 $VRTX
Pacific Biosciences to Incur Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:50PM CDT
We expect Pacific Biosciences (PACB) to post narrower-than-expected third quarter loss.
VRTX: 108.16 (+3.39), PACB: 5.56 (unch), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), BMRN: 74.71 (+3.71), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:05PM CDT
Alexion (ALXN) is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), ALXN: 174.48 (+6.28), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Celgene (CELG) Q3 Earnings to Be Overrun by Expenses? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:50PM CDT
Celgene (CELG) is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57), CELG: 94.97 (+2.97)
FDA Advisory Committee Recommends Approval of KALYDECO(R) (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Business Wire - Tue Oct 21, 3:47PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO(R) (ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene, which is the indication being reviewed by the FDA.
VRTX: 108.16 (+3.39)
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:15PM CDT
GlaxoSmithKline (GSK) is scheduled to report third-quarter 2014 results on Oct 22.
VRTX: 108.16 (+3.39), MRK: 55.13 (+1.08), AZN: 69.00 (+1.05), LGND: 50.65 (+0.41), GSK: 43.63 (+0.02)
Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:45PM CDT
Biogen Idec Inc. (BIIB) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22.
BIIB: 326.77 (+15.36), VRTX: 108.16 (+3.39), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
180 Million People Have This Disease, Yet Few Are Aware of It
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 19, 6:47AM CDT
Source: European Commission DG ECHO via Flickr Infectious diseases are everywhere, and according to Smart Global Health they're blamed for 16% of global deaths each year. Breaking these deaths down based on data from the World Health...
VRTX: 108.16 (+3.39), GILD: 106.67 (+4.46), OSUR: 8.46 (+0.34)
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 108.16 (+3.39), ALNY: 88.92 (+0.93), GILD: 106.67 (+4.46), SRPT: 22.49 (-0.34), AUXL: 31.12 (+0.53), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 1.56% Sell Off
Comtex SmarTrend(R) - Tue Oct 14, 5:04PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $103.30 to a high of $107.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $103.78 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 108.16 (+3.39)
SmarTrend Watching for Potential Rebound in Shares of Vertex Pharmaceuticals After 1.56% Loss
Comtex SmarTrend(R) - Tue Oct 14, 5:03PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $103.30 to a high of $107.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $103.78 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 108.16 (+3.39)
Vertex to Announce Third Quarter 2014 Financial Results on October 28
Business Wire - Tue Oct 14, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
VRTX: 108.16 (+3.39)
Gilead Sciences, inc. Stock's Green Light Sparks Offensive
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 13, 7:27AM CDT
Source: Gilead Sciences. Gilead Sciences got the FDA go-ahead last week for its next generation Harvoni, a hepatitis C drug that offers what amounts to a functional cure for most hepatitis C patients. The approval isn't a surprise. Industry...
VRTX: 108.16 (+3.39), ESRX: 74.03 (+2.51), GILD: 106.67 (+4.46), UNH: 90.95 (+2.41)
Upgrade Alert for Vertex Pharmaceuticals (VRTX)
Comtex SmarTrend(R) - Mon Oct 13, 7:04AM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $104.73 on volume of 2.0 million shares, above average daily volume of 1.8 million. Over the past year, Vertex Pharmaceuticals has traded in a range of $58.06 to $116.88 and closed yesterday at $104.73, 80% above that low. Over the past week, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 1.2%.
VRTX: 108.16 (+3.39)
Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:43PM CDT
Vertex Pharmaceuticals Incorporated (VRTX) announced updates on its cystic fibrosis (CF) drug Kalydeco (ivacaftor) and other pipeline candidates.
VRTX: 108.16 (+3.39), SHPG: 185.80 (+1.21), SCMP: 8.00 (+0.06), PCRX: 100.85 (+1.94)
Stock Market News for October 09, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 9:10AM CDT
Markets snapped two straight days of losses to end in the green on Wednesday after Fed Minutes reassured investors that the central bank will be patient before hiking rates
VRTX: 108.16 (+3.39), GILD: 106.67 (+4.46), ALXN: 174.48 (+6.28), COST: 130.28 (+1.86), ABBV: 56.29 (+1.88)
Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
Business Wire - Thu Oct 09, 8:32AM CDT
---Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements in lung function through 48 weeks of treatment with lumacaftor in combination with ivacaftor in people with two copies of the F508del mutation-
VRTX: 108.16 (+3.39)
Why You Shouldn't Bet Against Vertex Pharmaceuticals (VRTX) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 7:55AM CDT
Vertex Pharmaceuticals is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
VRTX: 108.16 (+3.39)
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 08, 7:14AM CDT
Sunesis's (SNSS) experimental cancer treatment failed to achieve the primary endpoint in a pivotal study, sending the shares down 78%.
VRTX: 108.16 (+3.39), CMRX: 30.24 (-0.42), GILD: 106.67 (+4.46), INCY: 52.44 (+1.65), ALXN: 174.48 (+6.28), SNSS: 1.47 (-0.03), REGN: 381.01 (+14.88)
Senior Housing Properties Trust Announces LEED(R) Gold Certification of the Vertex Pharmaceuticals Biotech Buildings
Business Wire - Wed Oct 08, 7:01AM CDT
Senior Housing Properties Trust (NYSE: SNH) today announced that the Vertex Pharmaceuticals biotech buildings located in Boston's Seaport District have been formally awarded LEED(R) Gold Certification. The LEED rating system, developed by the U.S. Green Building Council (USGBC), is the foremost program for buildings, homes and communities that are designed, constructed, maintained and operated for improved environmental and human health performance.
VRTX: 108.16 (+3.39), SNH: 22.00 (-0.14)
Pacific Biosciences to Incur Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:50PM CDT
We expect Pacific Biosciences (PACB) to post narrower-than-expected third quarter loss.
VRTX: 108.16 (+3.39), PACB: 5.56 (unch), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), BMRN: 74.71 (+3.71), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:05PM CDT
Alexion (ALXN) is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), ALXN: 174.48 (+6.28), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
Celgene (CELG) Q3 Earnings to Be Overrun by Expenses? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:50PM CDT
Celgene (CELG) is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 108.16 (+3.39), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57), CELG: 94.97 (+2.97)
FDA Advisory Committee Recommends Approval of KALYDECO(R) (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Business Wire - Tue Oct 21, 3:47PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO(R) (ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene, which is the indication being reviewed by the FDA.
VRTX: 108.16 (+3.39)
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:15PM CDT
GlaxoSmithKline (GSK) is scheduled to report third-quarter 2014 results on Oct 22.
VRTX: 108.16 (+3.39), MRK: 55.13 (+1.08), AZN: 69.00 (+1.05), LGND: 50.65 (+0.41), GSK: 43.63 (+0.02)
Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:45PM CDT
Biogen Idec Inc. (BIIB) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22.
BIIB: 326.77 (+15.36), VRTX: 108.16 (+3.39), LGND: 50.65 (+0.41), TEVA: 53.26 (+1.57)
180 Million People Have This Disease, Yet Few Are Aware of It
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 19, 6:47AM CDT
Source: European Commission DG ECHO via Flickr Infectious diseases are everywhere, and according to Smart Global Health they're blamed for 16% of global deaths each year. Breaking these deaths down based on data from the World Health...
VRTX: 108.16 (+3.39), GILD: 106.67 (+4.46), OSUR: 8.46 (+0.34)
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 108.16 (+3.39), ALNY: 88.92 (+0.93), GILD: 106.67 (+4.46), SRPT: 22.49 (-0.34), AUXL: 31.12 (+0.53), AMGN: 144.09 (+6.58), ABBV: 56.29 (+1.88)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 1.56% Sell Off
Comtex SmarTrend(R) - Tue Oct 14, 5:04PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $103.30 to a high of $107.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $103.78 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 108.16 (+3.39)
SmarTrend Watching for Potential Rebound in Shares of Vertex Pharmaceuticals After 1.56% Loss
Comtex SmarTrend(R) - Tue Oct 14, 5:03PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $103.30 to a high of $107.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $103.78 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 108.16 (+3.39)
Vertex to Announce Third Quarter 2014 Financial Results on October 28
Business Wire - Tue Oct 14, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
VRTX: 108.16 (+3.39)
Gilead Sciences, inc. Stock's Green Light Sparks Offensive
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 13, 7:27AM CDT
Source: Gilead Sciences. Gilead Sciences got the FDA go-ahead last week for its next generation Harvoni, a hepatitis C drug that offers what amounts to a functional cure for most hepatitis C patients. The approval isn't a surprise. Industry...
VRTX: 108.16 (+3.39), ESRX: 74.03 (+2.51), GILD: 106.67 (+4.46), UNH: 90.95 (+2.41)
Upgrade Alert for Vertex Pharmaceuticals (VRTX)
Comtex SmarTrend(R) - Mon Oct 13, 7:04AM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $104.73 on volume of 2.0 million shares, above average daily volume of 1.8 million. Over the past year, Vertex Pharmaceuticals has traded in a range of $58.06 to $116.88 and closed yesterday at $104.73, 80% above that low. Over the past week, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 1.2%.
VRTX: 108.16 (+3.39)
Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:43PM CDT
Vertex Pharmaceuticals Incorporated (VRTX) announced updates on its cystic fibrosis (CF) drug Kalydeco (ivacaftor) and other pipeline candidates.
VRTX: 108.16 (+3.39), SHPG: 185.80 (+1.21), SCMP: 8.00 (+0.06), PCRX: 100.85 (+1.94)
Stock Market News for October 09, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 9:10AM CDT
Markets snapped two straight days of losses to end in the green on Wednesday after Fed Minutes reassured investors that the central bank will be patient before hiking rates
VRTX: 108.16 (+3.39), GILD: 106.67 (+4.46), ALXN: 174.48 (+6.28), COST: 130.28 (+1.86), ABBV: 56.29 (+1.88)
Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
Business Wire - Thu Oct 09, 8:32AM CDT
---Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements in lung function through 48 weeks of treatment with lumacaftor in combination with ivacaftor in people with two copies of the F508del mutation-
VRTX: 108.16 (+3.39)
Why You Shouldn't Bet Against Vertex Pharmaceuticals (VRTX) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 7:55AM CDT
Vertex Pharmaceuticals is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
VRTX: 108.16 (+3.39)
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 08, 7:14AM CDT
Sunesis's (SNSS) experimental cancer treatment failed to achieve the primary endpoint in a pivotal study, sending the shares down 78%.
VRTX: 108.16 (+3.39), CMRX: 30.24 (-0.42), GILD: 106.67 (+4.46), INCY: 52.44 (+1.65), ALXN: 174.48 (+6.28), SNSS: 1.47 (-0.03), REGN: 381.01 (+14.88)
Senior Housing Properties Trust Announces LEED(R) Gold Certification of the Vertex Pharmaceuticals Biotech Buildings
Business Wire - Wed Oct 08, 7:01AM CDT
Senior Housing Properties Trust (NYSE: SNH) today announced that the Vertex Pharmaceuticals biotech buildings located in Boston's Seaport District have been formally awarded LEED(R) Gold Certification. The LEED rating system, developed by the U.S. Green Building Council (USGBC), is the foremost program for buildings, homes and communities that are designed, constructed, maintained and operated for improved environmental and human health performance.
VRTX: 108.16 (+3.39), SNH: 22.00 (-0.14)
